1 / 5

Global Parkinson’s Disease Drug Market Industry Analysis and Forecast 2022-2028

The Global Parkinsonu2019s disease market is anticipated to grow at a significant CAGR during the forecast period (2022-2028).

omrglobal
Download Presentation

Global Parkinson’s Disease Drug Market Industry Analysis and Forecast 2022-2028

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research Parkinson’s Disease Drug Market Growth, Analysis Report, Share, Trends and Overview 2022-2028 Request https://www.omrglobal.com/request-sample/parkinsons-disease-drug a sample of our report on Parkinson’s Disease Drug Market: ------------------------------------------------------------------------------------ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803040404 The Global Parkinson’s disease market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Pharmaceutical firms are developing new and improved therapies for Parkinson’s disease (PD). Recently, there have been some major product launches in Parkinson’s disease. For instance, in February 2022, Avion Pharmaceuticals LLC announced the commercial launch of DHIVY, the first and only carbidopa/ levodopa (CD/LD) fractional tablet designed to be divided. Avion gained approval for DHIVY from the FDA in Nov 2021. This unique design enables more precise medication for those with Parkinson’s disease (PD). Also, government funding for research and massive utilization of L- Dopa, asymptomatic dopamine replacement treatment, and the nigrostriatal system expects a boost to the market in the coming years. A full report of Parkinson’s Disease Drug Market is available at: https://www.omrglobal.com/request- sample/parkinsons-disease-drug

  2. The shifting of research activities from symptomatic treatment to Parkinson’s disorder modifying treatment will create growth for Parkinson’s disease treatment industry over the forthcoming years. For instance, Kyowa Kirin Co Ltd a Japanese Pharmaceutical and biotechnology company announced the U.S. Food and Drug Administration (FDA) approval for medicine NOURIANZ (istradefylline). For instance, in Feb 2020, Sun Pharma launched severe nodular acne management capsules in the US. It is launched for patients who are below 12 years of age or older. It can be taken with or without food. To learn more about this report request a sample copy @https://www.omrglobal.com/request- sample/parkinsons-disease-drug Market Coverage • The market number available for – 2022-2028 • Base year- 2021 • Forecast period- 2022-2028 • Segment Covered- By Mechanism of Action • Regions Covered- oNorth America oEurope oAsia-Pacific oRest of the World • Plc, Bausch Health Companies Inc., Cipla Inc., Daiichi Sankyo Espha Co., Ltd., and others. Competitive Land- AbbVie Inc., Merck & Co. Inc., Boehringer Ingelheim GmbH, GlaxoSmithKline Key questions addressed by the report • What is the market growth rate? • Which segment and region dominate the market in the base year? • Which segment and region will project the fastest growth in the market?

  3. • How COVID-19 impact the market? o Deviation from the pre-COVID-19 forecast o Most affected region and segment • Who is the leader in the market? • How players are addressing challenges to sustain growth? • Where is the investment opportunity? Global Parkison’s Disease Drug Market Report Segment By Mechanism of Action Dopamine Agonists Anticholinergic MAO-B Inhibitors Amantadine Carbidopa-levodopa COMT Inhibitors Others Global Parkinson’s Disease Drug Market-Segment by Region North America United States Canada Europe Germany United Kingdom France Spain Italy Rest of Europe

  4. Asia-Pacific China Japan India Rest of Asia-Pacific Rest of the World Middle East & Africa Latin America Company Profiles AbbVie Inc Apotex Inc Axovant Gene Therapies Ltd Boston Scientific Corp Cipla Inc Eisai Co Ltd Eli Lily & Co Impax Laboratories Inc Mylan NV Novartis International AG Pfizer Inc Sanofi SA Teva Pharmaceuticals Industries Ltd Wockhardt Ltd Orion Corp Reasons to Buying From us – 1.We cover more than 15 major industries, further segmented into more than 90 sectors. 2.More than 120 countries are for analysis. 3.Over 100+ paid data sources mined for investigation. 4.Our expert research analysts answer all your questions before and after purchasing your report.

  5. About Orion Market Research OMR provide global and regional market reports of various domains such as healthcare, energy, IT, chemicals, and automobiles. OMR provide a 360-degree view of the market with parametric analysis, key market insights, key findings, statistical forecasts, competitive landscape, extensive segmentation, key trends, strategic recommendations and detailed company profiles. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: anurag@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404

More Related